GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » electroCore Inc (NAS:ECOR) » Definitions » 1-Year Share Buyback Ratio

ECOR (electroCore) 1-Year Share Buyback Ratio : -10.80% (As of Dec. 2024 )


View and export this data going back to 2018. Start your Free Trial

What is electroCore 1-Year Share Buyback Ratio?

Shares Outstanding (EOP) are shares that have been authorized, issued, and purchased by investors and are held by them.

1-Year Share Buyback Ratio measures the proportion of a company's outstanding shares repurchased over the past year, calculated as the percentage change in shares outstanding from the previous year to the current year. A positive ratio may indicates share buybacks over the period, while a zero or negative ratio suggests no buybacks or potential share issuance. electroCore's current 1-Year Share Buyback Ratio was -10.80%.

ECOR's 1-Year Share Buyback Ratio is ranked worse than
64.35% of 575 companies
in the Medical Devices & Instruments industry
Industry Median: -2.6 vs ECOR: -10.80

Competitive Comparison of electroCore's 1-Year Share Buyback Ratio

For the Medical Devices subindustry, electroCore's 1-Year Share Buyback Ratio, along with its competitors' market caps and 1-Year Share Buyback Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

electroCore's 1-Year Share Buyback Ratio Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, electroCore's 1-Year Share Buyback Ratio distribution charts can be found below:

* The bar in red indicates where electroCore's 1-Year Share Buyback Ratio falls into.


;
;

electroCore 1-Year Share Buyback Ratio Calculation

electroCore's 1-Year Share Buyback Ratio for the quarter that ended in Dec. 2024 is calculated as

1-Year Share Buyback Ratio=(Shares Outstanding (EOP) (Dec. 2023 ) - Shares Outstanding (EOP) (Dec. 2024 )) / Shares Outstanding (EOP) (Dec. 2023 )
=(6.003 - 6.651) / 6.003
=-10.8%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

electroCore  (NAS:ECOR) 1-Year Share Buyback Ratio Explanation

A positive ratio may indicates share buybacks over the period, while a zero or negative ratio suggests no buybacks or potential share issuance.

Be Aware

Investors usually like share buybacks. But as pointed by Warren Buffett, only if a company buys back shares at the prices below the stock's intrinsic value, it rewards remaining shareholders. If a company buys its overvalued stocks back, it destroys shareholder value.

electroCore 1-Year Share Buyback Ratio Related Terms

electroCore Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » electroCore Inc (NAS:ECOR) » Definitions » 1-Year Share Buyback Ratio
Comparable Companies
MODD NVNO TELA APYX PTHL OPGN VNRX RDGL HYPR RBOT ABT BSX SYK MDT XTER:SHL EW SZSE:300760 DXCM XAMS:PHIA ZBH
Traded in Other Exchanges
N/A
Address
200 Forge Way, Suite 205, Rockaway, NJ, USA, 07866
Website
https://www.electrocore.com
electroCore Inc is a commercial stage bioelectronic medicine company with a platform for non-invasive vagus nerve stimulation therapy initially focused on neurology. The company's product gammaCore is Food and Drug Administration cleared in the United States for adjunctive use for the preventive treatment of cluster headache in adult patients, the acute treatment of pain associated with episodic cluster headache in adult patients, the acute treatment of pain associated with migraine headache in adult patients, and the prevention of migraine in adult patients, The use of gammaCore by adolescent patients and Treatment of hemicrania continua and paroxysmal hemicrania in adult patients.
Executives
Daniel S Goldberger director, officer: Chief Executive Officer 24 CARPENTER ROAD, CHESTER NY 10918
Thomas J. Errico director, 10 percent owner 150 ALLEN ROAD, SUITE 201, BASKING RIDGE NJ 97920
John P Gandolfo director 62 TERRACE ROAD, WAYNE NJ 07470
Joseph P Errico director, 10 percent owner, officer: See Remarks 150 ALLEN ROAD, SUITE 201, BASKING RIDGE NJ 07920
Trevor J Moody director 150 ALLEN ROAD, SUITE 201, BASKING RIDGE NJ 07920
Julie Ann Goldstein director 205 FORGE WAY, ROCKAWAY NJ 07866
Patricia Wilber director 205 FORGE WAY, SUITE 205, ROCKAWAY NJ 07866
Brian M Posner officer: Chief Financial Officer 1590 REED ROAD, PENNINGTON NJ 08534
Tullis James L L director 100 FIRST STAMFORD PLACE, STAMFORD CT 06907
Thomas M Patton director C/O OSTEOTCH INC., 51 JAMES WAY, EATONTOWN NJ 07724
F Peter Cuneo director 10 EAST 40TH ST, NEW YORK NY 10016
Stephen Ondra director 150 ALLEN ROAD, SUITE 201, BASKING RIDGE NJ 07920
Nicholas Colucci director 150 ALLEN ROAD, SUITE 201, BASKING RIDGE NJ 07920
Michael G Atieh director MERCK MEDCO MANAGED CARE INC, 100 SUMMIT AVE, MONTVALE NJ 07645
Carrie Smith Cox director SCHERING-PLOUGH CORPORATION, 2000 GALLOPING HILL ROAD, KENILWORTH NJ 07033